<DOC>
	<DOCNO>NCT00843713</DOCNO>
	<brief_summary>Recent study suggest HIV patient increase risk cardiovascular event ; however , mechanisms underlie increase risk remain unclear . Our group one first demonstrate HIV infection independently associate accelerated atherosclerosis , measure carotid artery-intima medium thickness ( IMT ) , HIV-associated inflammation may drive accelerated atherosclerosis . The mechanism HIV disease independent drug-specific toxicity increase risk cardiovascular disease HAART know . We hypothesize even well control HIV infection independently associate cardiovascular risk decrease HIV-associated inflammation add new antiretroviral agent also decrease cardiovascular risk . We perform small clinical trial approximately 50 HIV-infected patient study relationship HIV infection , inflammation , thrombosis , atherogenic lipoprotein , measure atherosclerosis . We propose follow specific aim : Aim 1 : To determine influence traditional novel marker inflammation endothelial function IMT progression ; Aim 2 : To determine `` intensification '' raltegravir subject long-term antiretroviral therapy clinically undetectable HIV RNA level improve endothelial function , determine effect mediate alteration inflammatory marker , lipoproteins and/or thrombotic factor . For Aim 2 , subject 2 randomize , double-blind , placebo-controlled raltegravir intensification study ask co-enroll cardiovascular study .</brief_summary>
	<brief_title>Effect Raltegravir Endothelial Function HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Stable antiretroviral therapy least 12 month 2 . All plasma HIV RNA level within past year must level detection ( &lt; 50 copy RNA/mL ) , although isolated single value &gt; 50 &lt; 200 copy allow . 3 . Screening plasma HIV RNA level &lt; 50 copy RNA/mL 4 . &gt; 90 % adherence therapy within precede 30 day , determine selfreport 5 . Females childbearing potential must negative serum pregnancy test screen agree use doublebarrier method contraception throughout study period . 6 . CD4 &lt; 350 cells/mm3 least one year ( `` immunologic nonresponder '' ) CD4 &gt; =350 cells/mm3 least one year ( `` immunologic responder '' ) . 1 . Ongoing prior use integrase inhibitor R5 inhibitor . 2 . Patients plan modify exist antiretroviral therapy next 24 week reason 3 . Serious illness require hospitalization parental antibiotic within precede 3 month 4 . Concurrent recent exposure immunomodulatory drug 5 . Advanced liver disease active hepatitis B C 6 . Patients systolic blood pressure &lt; 100/70 7 . Starting stop statin therapy trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>endothelium</keyword>
	<keyword>inflammation</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>